ETST Earth Science Tech, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1538495 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.1%
TTM net income YoY33.6%
TTM EPS YoY-7.7%
Revenue 3-yr CAGR149.7%
Net income 3-yr CAGR144.1%
Margins
Gross margin70.2%
Operating margin—
Net margin11.0%
FCF margin2.2%
EBITDA margin—
Returns
ROE57.5%
ROA38.5%
ROIC (approx.)—
Asset turnover3.50x
Leverage & solvency
Liabilities / assets25.6%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.43x
Accruals ratio22.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $35.70M | $33.12M | $11.95M | $48,537 | $14,123 |
| Cost of revenue | $10.21M | $8.82M | $4.13M | $26,477 | $22,639 |
| Gross profit | $25.49M | $24.30M | $7.83M | $22,060 | -$8,516 |
| R&D expense | — | — | — | $0 | $0 |
| SG&A expense | $3.57M | $4.15M | $166,976 | $231,890 | $116,064 |
| Operating income | — | — | $892,349 | -$936,683 | -$226,706 |
| Interest expense | $16,327 | $21,189 | $4,125 | $47,433 | $86,706 |
| Pretax income | $3.09M | $3.37M | $825,142 | -$365,405 | $3.17M |
| Income tax | -$511,676 | $116,776 | $13,003 | — | — |
| Net income | $3.63M | $3.25M | $812,139 | -$365,405 | $3.17M |
| EBITDA | — | — | $1.04M | -$919,192 | -$226,706 |
| EPS (basic) | 0.01 | 0.01 | 0.00 | -0.00 | 0.06 |
| EPS (diluted) | 0.01 | 0.01 | 0.00 | -0.00 | — |
| Weighted avg. shares (diluted) | 293.07M | 303.52M | 309.69M | 145.87M | — |
| Banking | |||||
| Net interest income | — | -$21,189 | -$67,207 | -$47,433 | — |
| Balance sheet | |||||
| Cash & equivalents | $796,797 | $1.47M | $697,721 | $35,756 | $26,942 |
| Receivables | $356,054 | $129,064 | $235,423 | $0 | — |
| Inventory | $682,059 | $503,938 | $315,738 | $10,260 | — |
| Current assets | $3.72M | $3.11M | $1.26M | $46,016 | $26,942 |
| PP&E, net | $1.52M | $1.38M | $135,352 | $143,213 | — |
| Goodwill | $2.65M | $2.30M | $2.30M | $2.30M | — |
| Intangibles | $208,170 | $96,885 | $28,441 | $35,276 | — |
| Total assets | $8.97M | $7.07M | $3.88M | $2.73M | $76,942 |
| Current liabilities | $1.93M | $3.15M | $1.49M | $1.31M | $1.88M |
| Short-term debt | — | $179,488 | $30,592 | $604,767 | $780,694 |
| Long-term debt | — | — | $60,559 | $204,408 | $780,694 |
| Total debt | — | — | $91,151 | $809,175 | $1.56M |
| Total liabilities | $1.93M | $3.22M | $1.63M | $1.61M | $1.88M |
| Shareholders' equity | $7.01M | $3.85M | $2.25M | $1.12M | -$1.81M |
| Net debt | — | — | -$606,570 | $773,419 | $1.53M |
| Shares outstanding | 291.32M | 294.30M | 309.98M | 282.61M | 53.85M |
| Cash flow statement | |||||
| Operating cash flow | $1.94M | $4.37M | $1.21M | -$1.01M | -$168,106 |
| Capital expenditure | $756,619 | $753,165 | $26,520 | — | — |
| Free cash flow | $1.18M | $3.62M | $1.18M | — | — |
| Investing cash flow | -$1.90M | -$1.88M | -$26,520 | — | $1,712 |
| Financing cash flow | -$712,917 | -$1.72M | -$517,886 | $1.02M | $173,175 |
| Depreciation & amortization | $284,396 | $53,951 | $149,749 | $17,491 | $0 |
| Stock-based compensation | — | — | $300 | $4,500 | — |
| Share buybacks | $471,410 | $1.47M | $178,000 | — | — |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.